Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06246318 Completed - Virtual Reality Clinical Trials

Effects of VR in Children With DCD: Randomized Controlled Trial

Start date: January 25, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to examine the effect of VR application on motor, cognitive and sensory-perceptual skills, and activity and participation levels in children with DCD. The hypotheses on which the study proposal is based are as follows: 1. H0: VR application has no effect on motor skills in children with DCD. H1: VR application has an effect on motor skills in children with DCD. 2. H0: VR application has no effect on cognitive skills in children with DCD. H1: VR application has an effect on cognitive skills in children with DCD. 3. H0: VR application has no effect on sensory-perception skills in children with DCD. H1: VR application has an effect on sensory-perception skills in children with DCD. 4. H0: VR application has no effect on the functional independence levels in daily living activities in children with DCD. H1: VR application has an effect on the functional independence levels in daily living activities in children with DCD. 5. H0: VR application has no effect on participation levels in children with DCD. H1: VR application has an effect on participation levels in children with DCD.

NCT ID: NCT06244550 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors

Start date: September 22, 2021
Phase: N/A
Study type: Interventional

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease globally, with an estimated prevalence of approximately 15 to 30%. The incidence of NAFLD is even higher, reaching up to 58%, in individuals who are overweight or obese. The pathogenesis of NAFLD is complex and not fully understood. The metabolism of carbohydrates contributes to the development of NAFLD, as it increases the enzymatic activity of lipid synthesis in the liver, depleting adenosine triphosphate (ATP) rapidly and causing stress on mitochondria and endoplasmic reticulum. The multifunctional protein Glycine N-methyltransferase (GNMT) plays a regulatory role in liver carbohydrate metabolism, and its expression is downregulated in the liver tissues of NAFLD. While weight loss and lifestyle adjustments are helpful in controlling NAFLD, effective pharmacological or healthcare interventions for NAFLD patients are currently lacking. Insulin resistance is crucial in the pathogenesis of NAFLD, suggesting that drugs improving insulin sensitivity, such as metformin, might have therapeutic effects. However, recent large-scale clinical trial results have not supported this hypothesis. Investigators propose that the mitochondrial inhibitory effects of metformin may be related to this discrepancy, and the negative effects may be reversed through food containing substances promoting GNMT gene expression, such as Ganwei (as know as "HepatoKeeper"). Preliminary animal experiments also show that the combined use of metformin and GNMT enhancers effectively eliminates liver lipid droplet accumulation and improves liver inflammation in a NAFLD mouse model, surpassing the effects of either drug used alone. Based on these findings, our team designed the medication treatment group for this clinical trial, aiming to investigate whether the combination of Ganwei and metformin produces a synergistic effect in humans. Ganwei compound herbal extract capsules contain extracts from natural foods such as Schisandra chinensis, Paeonia lactiflora, and Punica granatum. Among them, Paeonia lactiflora is known to contain components that enhance GNMT expression. Animal and cell experiments have demonstrated its potential for repairing liver damage and inflammation. This trial aims to assess the impact of orally administering Ganwei compound herbal extract capsules on participants and evaluate its effects on fatty liver, liver fibrosis, and metabolic indicators.

NCT ID: NCT06241079 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma

Start date: March 31, 2003
Phase:
Study type: Observational

The goal of this multicenter retrospective cohort study is to evaluate the impact of different pathological regression types on survival and recurrence patterns, with a particular focus on ypT0N+ patients in patients with esophageal squamous cell carcinoma. The main questions it aims to answer are the survival and recurrence patterns among the different pathological regression types in patients with esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.

NCT ID: NCT06241066 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma

Start date: January 1, 2014
Phase:
Study type: Observational

Retrospective analysis of the presence and maturity of tertiary lymphoid structures in pathological sections of patients with esophageal squamous cell carcinoma after surgical treatment. Pay attention to the overall survival and disease free survival of these esophageal squamous cell carcinoma patients.

NCT ID: NCT06237764 Completed - Risk Reduction Clinical Trials

Genetic and Risk Factors in Exfoliation Glaucoma Patients

Start date: January 1, 2014
Phase:
Study type: Observational

Prospective non-randomised cohort study enrolling patients with exfoliation glaucoma. All patients were ophthalmological examined at inclusion. Blood samples were taken for genetic analysis.

NCT ID: NCT06235853 Completed - Bladder Cancer Clinical Trials

Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer

Start date: January 1, 2020
Phase:
Study type: Observational

Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across the world. The goal of this prospective study was to evaluate the prognostic value of novel non-muscle invasive bladder cancer (NMIBC) biomarkers for predicting disease recurrence or progression after radical transurethral resection of bladder tumour (TURBT). The data obtained from this study may help physicians identify patients who are at greater risk of NMIBC recurrence or progression and require close supervision.

NCT ID: NCT06235762 Completed - Hypertension Clinical Trials

The Effects of Nutritional Intervention on Health Parameters in Participants With Type 2 Diabetes Mellitus

Start date: August 16, 2020
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effects of nutritional intervention on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus. Participants will be distributed into 2 groups (control and intervention). Participants in the control group will only undergo conventional medical assessment and participants in the intervention group will receive the same medical care, concomitantly with nutritional assessment. The nutritional intervention is expected to reduce anthropometric data, glycemic and cardiovascular parameters in participants with T2DM, as opposed to the control group.

NCT ID: NCT06234774 Completed - Clinical trials for Postoperative Respiratory Complication

Postoperative Pulmonary Complications in Robotic Versus Non-robotic Laparoscopic Surgery

LapRas
Start date: January 14, 2013
Phase:
Study type: Observational

This secondary analysis aims to identify factors associated with the development of postoperative pulmonary complications (PPCs) in patients undergoing abdominal surgery, pooling and analyzing the data of two worldwide prospective studies, the 'Epidemiology, Practice of Ventilation and Outcome for Patients at Increased Risk of Postoperative Pulmonary Complications' (LAS VEGAS, NCT01601223) and the 'Assessment of Ventilatory management during general AnesThesia for Robotic surgery and its effects on postoperative pulmonary complications' (AVATaR, NCT02989415). The primary aim is to compare the incidence of PPCs between patients undergoing non-robotic surgery versus patients undergoing robot-assisted surgery. One secondary aim is to determine which factors are associated with the occurrence of PPCs. The investigators hypothesize that differences in the occurrence of PPCs between the two surgery groups are more driven by differences in duration of anesthesia than by the intensity of ventilation.

NCT ID: NCT06234280 Completed - Clinical trials for Moderate or Severe Claudication (Rutherford Category 2 or 3)

Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease

K-ELUVIA
Start date: May 11, 2018
Phase:
Study type: Observational

- Prospective, multi-center single-arm observational study - A total of 100 subjects with femoropopliteal artery disease who meet all inclusion and exclusion criteria will be included. - Patients will be followed clinically for 24 months after the procedure. - An imaging study (duplex ultrasound, CT or catheter-based angiography) follow-up according to participating hospital's protocol will be performed at 12 months. - Ankle-brachial index, symptom status and presence of stent fracture will be evaluated at 12 months.

NCT ID: NCT06234046 Completed - Clinical trials for Spontaneous Bacterial Peritonitis

Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin

Start date: May 28, 2023
Phase: Phase 3
Study type: Interventional

The goal of this Randomized controlled trial is to assessment the efficacy of Rifaximin as a prophylaxis of SBP in comparison with ciprofloxacin in Egyptian patients. This randomized controlled trial included 80 Egyptian patients diagnosed with cirrhotic liver disease and ascites just recovered from SBP attack grouped into two groups as; Group (1) included 40 cases received Rifaximin as 550 mg twice daily dose for a six-months period and group (2) included 40 cases received Ciprofloxacin as 750 mg once weekly dose for a six-months period. All patients of the two groups were followed up for recurrence of SBP for 6 months. The study endpoints would be SBP, death, compliance failure, or liver transplantation.